郑振国,张妍,周旭晨

• 1:大连医科大学附属第一医院心内科

摘要(Abstract)：

目的对经皮冠状动脉介入治疗(PCI)的非ST段抬高急性冠状动脉综合征(NSTEACS)患者进行CYP2C19基因多态性检测,判明有无氯吡格雷药物代谢异常,指导PCI术后选择性应用抗血小板药物,随诊观察术后1个月及6个月的主要不良心血管事件(MACE),明确基因检测指导的治疗作用。方法 2013年5月至2014年5月大连医科大学附属第一医院心内科收治NSTE-ACS并接受PCI治疗的患者486例,连续分为CYP2C19基因多态性检测指导治疗组(A组237例,若呈氯吡格雷低代谢,则用替格瑞洛替换治疗)与常规治疗组(B组249例,PCI术后常规应用氯吡格雷治疗),分析两组患者术后1个月、6个月MACE发生情况。结果 A组237例患者中,43例(18.1%)基因检测为氯吡格雷低代谢,改用替格瑞洛治疗。术后1个月时总体MACE发生率A组显著低于B组(1.3%比5.2%,P=0.031),A组心肌梗死和死亡的总发生率显著低于B组(1.3%比3.6%,P=0.041)。术后6个月时,两组总体MACE发生率比较,差异无统计学意义(4.2%比6.8%,P=0.210),但A组仍保持较低趋势。结论接受PCI治疗的NSTE-ACS患者术后进行CYP2C19基因多态性检测,有助于对氯吡格雷低代谢患者进行针对性替换治疗,从而有效降低这部分患者术后1个月的临床MACE发生率,但是对于远期预后的影响需做进一步观察。

关键词(KeyWords)： 非ST段抬高急性冠状动脉综合征;经皮冠状动脉介入治疗;CYP2C19基因多态性;替格瑞洛

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郑振国,张妍,周旭晨

参考文献(References)：

• [1]Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC Guideline for the management of patients with non-STelevation Acute Coronary Syndromes:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2014,64:e139-e228.
• [2]Hamm CW,Bassand JP,Agewall S,et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardioloy(ESC).G Ital Cardiol(Rome),2012,13:171-228.
• [3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南.中华心血管病杂志,2012,40:353-367.
• [4]郭新贵.解读欧美指南——再议新型P2Y12抑制剂治疗地位.中国介入心脏病学杂志,2015,23:55-58.
• [5]Shuldiner AR,O'Connell JR,Bliden KP,et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA,2009,302:849-857.
• [6]Frére C,Cuisset T,Gaborit,B,et al.The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.J Thromb Haemost,2009,7:1409-1411.
• [7]Mishkel GJ,Moore AL,Markwell S,et al.Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents.J Am Coll Cardiol,2007,49:181-184.
• [8]Luscher TF,Steffel J,Eberli FR,et al.Drug-eluting stent and coronary thrombosis:biological mechanisms and clinical implications.Circulation,2007,115:1051-1058.
• [9]Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomized double-blind study.Lancet,2010,375:283-293.